Literature DB >> 17072647

Acute exacerbation of hepatitis in a boy with chronic HCV genotype-2 infection after a 9-year period of normal transaminases levels.

Hitoshi Tajiri1, Yuri Etani, Sotaro Mushiake, Yasuhiro Hasegawa, Keiichi Ozono.   

Abstract

We report on a boy with HCV genotype-2a infection who presented with a severe degree of ALTflare after 9 years of asymptomatic period and was treated with pegylated interferon and ribavirin. We suggest that children with HCV genotype-2 infection who show a significant ALT flare should be treated with anti-viral therapies in order to avoid progression of hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072647     DOI: 10.1007/s00431-006-0267-0

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  5 in total

1.  Risk of alanine aminotransferase flare-up among asymptomatic hepatitis C virus RNA carriers: a 10-year follow-up study.

Authors:  K Tsuji; K Yamasaki; M Yamanishi; M Kawakami; S Shirahama
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

Review 2.  Children with hepatitis C.

Authors:  Maureen M Jonas
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare-up.

Authors:  Nobuhiko Hiraga; Fumitaka Suzuki; Norio Akuta; Yoshiyuki Suzuki; Hitomi Sezaki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Marie Matsuda; Sachiko Watabiki; Junko Satoh; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2005-02       Impact factor: 2.327

4.  Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough.

Authors:  M G Rumi; F De Filippi; M F Donato; E Del Ninno; M Colombo
Journal:  J Viral Hepat       Date:  2002-01       Impact factor: 3.728

5.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.